Cargando…

Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats

Hepatocellular carcinoma (HCC) and type 2 diabetes mellitus (T2DM) are common clinical conditions, and T2DM is an independent risk factor for HCC. Sorafenib and lenvatinib, two multi-targeted tyrosine kinase inhibitors, are first-line therapies for advanced HCC, while canagliflozin, a sodium-glucose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Yanjun, Li, Ying, Guo, Caihui, Li, Yajing, Ma, Yinling, Dong, Zhanjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457773/ https://www.ncbi.nlm.nih.gov/pubmed/36080187 http://dx.doi.org/10.3390/molecules27175419

Ejemplares similares

Development of UPLC-MS/MS Method to Study the Pharmacokinetic Interaction between Sorafenib and Dapagliflozin in Rats
por: He, Xueru, et al.
Publicado: (2022)

A Simple UPLC/MS-MS Method for Simultaneous Determination of Lenvatinib and Telmisartan in Rat Plasma, and Its Application to Pharmacokinetic Drug-Drug Interaction Study
por: Cui, Yanjun, et al.
Publicado: (2022)

Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS
por: Li, Ying, et al.
Publicado: (2022)

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats
por: Karbownik, Agnieszka, et al.
Publicado: (2020)

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
por: Wang, Zhi, et al.
Publicado: (2023)

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer
por: Kim, Soo Young, et al.
Publicado: (2018)

Pharmacokinetic Drug Interaction Study of Sorafenib and Morphine in Rats
por: Karbownik, Agnieszka, et al.
Publicado: (2021)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Differences Between Sorafenib and Lenvatinib Treatment from Genetic and Clinical Perspectives for Patients with Hepatocellular Carcinoma
por: Wang, Lei, et al.
Publicado: (2022)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Shi, Tingting, et al.
Publicado: (2021)

Preclinical Pharmacokinetic Interaction and Histopathological Analyses of Hedyotis diffusa on Sorafenib in Rats
por: Ting, Chin-Tsung, et al.
Publicado: (2021)

QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats
por: Ding, Congyang, et al.
Publicado: (2022)

Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
por: Takinami, Masaki, et al.
Publicado: (2020)

Herb-Drug Interaction between the Traditional Hepatoprotective Formulation and Sorafenib on Hepatotoxicity, Histopathology and Pharmacokinetics in Rats
por: Ting, Chin-Tsung, et al.
Publicado: (2017)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Plasma Pharmacokinetic Determination of Canagliflozin and Its Metabolites in a Type 2 Diabetic Rat Model by UPLC-MS/MS
por: Dong, Song-tao, et al.
Publicado: (2018)

Effect of Rifampicin on the Pharmacokinetics of Lenvatinib in Healthy Adults
por: Shumaker, Robert C., et al.
Publicado: (2014)

Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction
por: Ma, Sai, et al.
Publicado: (2022)

Pharmacokinetics Interaction between Imatinib and Genistein in Rats
por: Wang, Zhe, et al.
Publicado: (2015)

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
por: Burgio, Valentina, et al.
Publicado: (2021)

Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis
por: Luo, Jia, et al.
Publicado: (2022)

The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism
por: Wang, Xianming, et al.
Publicado: (2017)

Impact of Local Liver Irradiation Concurrent Versus Sequential with Lenvatinib on Pharmacokinetics and Biodistribution
por: Tsai, Tung-Hu, et al.
Publicado: (2021)

Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2020)

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
por: Iijima, Hiroaki, et al.
Publicado: (2015)

In vivo assessment of the drug interaction between sorafenib and paracetamol in rats
por: Karbownik, Agnieszka, et al.
Publicado: (2020)

Differences in the pharmacokinetics and steady-state blood concentrations of orally administered lenvatinib in adult and juvenile rats
por: Du, Xiaoyue, et al.
Publicado: (2023)

Effects of Ketoconazole on the Pharmacokinetics of Lenvatinib (E7080) in Healthy Participants
por: Shumaker, Robert, et al.
Publicado: (2015)

Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study
por: Chen, Bowen, et al.
Publicado: (2022)

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2020)

Improvement of lenvatinib-induced nephrotic syndrome after adaptation to sorafenib in thyroid cancer: A case report
por: Yang, Che Hseuh, et al.
Publicado: (2020)

Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
por: Sekiguchi, Shuhei, et al.
Publicado: (2022)

Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment
por: Lee, I-Cheng, et al.
Publicado: (2022)

Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
por: Chiang, Hsueh-Chien, et al.
Publicado: (2023)

Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib
por: Eun, Jung Woo, et al.
Publicado: (2023)

A Pharmacokinetic Interaction Study of Sorafenib and Iced Teas in Rats Using UPLC-MS/MS: An Illustration of Beverage-Drug Interaction
por: Maher, Hadir M., et al.
Publicado: (2019)

Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by UPLC‐MS/MS
por: Xia, Mengming, et al.
Publicado: (2023)

Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting
por: Fukushima, Taito, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ev3j4btfcs6aa0d0buvvsahv91